BAYRY Q3 Earnings and Revenues Miss Estimates, Pharma Performs Well

What happened

Bayer reported third-quarter 2026 core earnings of 11 cents per American Depositary Receipt, missing the 13 cents estimate. Sales rose 4.1% to $11.57 billion but missed the $11.70 billion estimate, while Pharmaceuticals grew on Nubeqa and Kerendia.

Confirmed

Global impact / market context

Earnings fell short because higher taxes and a weaker financial result offset better operations, so profit per sale stayed thin even as revenue grew. Drug sales strength helps, but crop science weakness and regulatory problems can keep overall results uneven for investors.

Analyst inference

Bayer shares have gained 28.9% this year, ahead of the industry's 24.6% growth, so expectations were already high. A miss on both earnings and sales can pressure a stock that has run up, especially when pharmaceutical strength is offset by weaker crop science.

Analyst inference

What to watch

1. Crop Science sales declined 2.4% on an adjusted basis to €3.9 billion, as regulatory challenges and bad weather in Europe, the Middle East and Africa and Asia-Pacific weighed on results. Confirmed
2. Watch whether Bayer's Pharmaceuticals division can keep offsetting Crop Science weakness, since Nubeqa and Kerendia drove the strong drug performance this quarter and support overall revenue growth. Proposed
3. Higher tax expenses and a weaker financial result cut core earnings per share by 36.7%, so investors should watch whether these pressures ease or keep squeezing profit even if sales grow. Analyst inference

Evidence

• zacks.com